Atlas Trials

Inebilizumab and Rituximab in Neuromyelitis Optica Spectrum Disorders

Clinical trial NCT06068829 · UNKNOWN

Trial details

NCT number
NCT06068829
Sponsor
Feng Jinzhou
Status
UNKNOWN
Study type
OBSERVATIONAL
Neuromyelitis Optica Spectrum Disorders
Start date
2023-10-20
Primary completion
2024-06-30
Enrollment
80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.